April 14- U.S. drugstore chain operator Walgreen Co is under pressure from a group of shareholders to consider relocating to Europe to gain tax benefits, the Financial Times reported.» Read More
Just in the last month, two weight loss drugs have won the approval of the FDA, reports CNBC's Seema Mody.
CNBC's Eamon Javers reports on an apology made by HSBC's U.S. CEO regarding the money laundering scandal.
Federal prosecutors are uncovering what they say is another blatant rip-off of the Medicaid system, and U.S. Attorney Preet Bharara says 48 people are charged in a nationwide operation centered here in New York, reports CNBC's Scott Cohn.
The "Mad Money" host gets poetic and gives investors a glimpse of how the global economy might be seen through Charles Dickens' eyes.
Wal-Mart is responsible for 11 percent of the total U.S. retail sales, and CNBC's Courtney Reagan reports on the debate between economists over the company's costs and benefits of its impact on the retail landscape.
With the weight loss market heating up, stocks like Arena Pharmaceuticals may be spelling out a big rally for the drug retail space.
Last week, Celgene announced it was pulling its Revlimid application in Europe, and Mad Money host Jim Cramer explains why he thinks investors should buy into the stock now.
Airbus plans to build its first U.S. assembly line in Alabama, Arena Pharmaceutical's new anti-obesity drug is set to hit the market early 2013, and Peter Madoff will tentatively plead guilty, reports, CNBC's Brian Shactman and Seema Mody.
CNBC's David Faber reports Walgreens comparable sales are down 5.8% from a year ago.
The “Mad Money” host offers his earnings expectations for Time Warner, CVS Caremark, Garmin, Allergan and Clorox.
Walgreen is getting a pharmacy facelift and the chain, based in Illinois, is adding fancy food, more booze and amping up its drugstores. Kermit Crawford, Walgreen president, offers insight into the company's business strategies.
CNBC's Seema Mody reports the pharma sector is up about 8% and outperforming the S&P 500 this year.
CNBC's Brian Sullivan reports today's sunshine stock, Alexion Pharmaceuticals hit an all time high today.
The drug developer's stock took a hit Thursday, after data was released linking an ingredient in its weight loss treatment to an increased risk of birth defects.
Accused of running a $7B ponzi scheme, Allen Stanford was in court today and CNBC's Scott Cohn has the story.
The "Mad Money" host reveals what earnings and other event he plans to monitor.
CNBC's Courtney Reagan reports on lifted holiday retail sales at drug stores.
A breakdown of better-than-expected earnings from the generic drug maker, with Joseph Papa, Perrigo CEO.
Joseph Papa sits down with Cramer and explains why things are looking good for the private label drug maker.
Are pharmacy benefit managers becoming obsolete? CNBC's Herb Greenberg says consumers can now buy away from their PBM and insurance plans at Costco, Walmart, Target, and Walgreens.